Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Elliott, Lindsay S ^a   Henderson, John C ^b   Neradilek, Moni B ^c   Moyer, Nicolas A ^d   Ashcraft, Kristine C ^d   Thirumaran, Ranjit K ^d  

^a HARDING UNIVERSITY   (United States)

^b Unity Health White County Medical Center   (United States)

^c Mountain Whisper Light Statistics   (United States)

^d Genelex Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENETIC ALGORITHM; GENOTYPING TECHNIQUE; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HOME CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PHARMACOGENETICS; PILOT STUDY; POLYPHARMACY; PRESCRIPTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOFTWARE; CLINICAL DECISION SUPPORT SYSTEM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE EXPRESSION PROFILING; GENETICS; HOSPITALIZATION; MIDDLE AGED; OUTCOME ASSESSMENT; PHARMACOGENETIC VARIANT;

AGED; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENE EXPRESSION PROFILING; HOME CARE AGENCIES; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOGENOMIC VARIANTS; POLYPHARMACY; PROSPECTIVE STUDIES;

EID: 85011659668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170905     Document Type: Article

References (36)

1. Home health care services: Assessing payment adequacy and updating payments. Medicare Payment Advisory Commission March 2015 Report to the Congress: Medicare Payment Policy. 2015; (March):213-36.
2. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47(3):533-43. PMID: 2316538.
3. Hampton LM, Daubresse M, Chang HY, Alexander GC, Budnitz DS. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry. 2014; 71(9):1006-14. doi:10.1001/jamapsychiatry.2014.436 PMID: 25006837.
4. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. doi:10.1016/j.pharmthera.2012.12.007 PMID: 23333322.
5. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science. 1999; 286(5439):487-91. PMID: 10521338.
6. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21):2211-21. doi:10.1056/NEJMra032424PMID: 15917386.
7. Cardelli M, Marchegiani F, Corsonello A, Lattanzio F, Provinciali M. A review of pharmacogenetics of adverse drug reactions in elderly people. Drug Saf. 2012; 35 Suppl 1:3-20.
8. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and overthe- counter medications and dietary supplements among older adults in the United States. JAMA. 2008; 300(24):2867-78. doi:10.1001/jama.2008.892 PMID: 19109115.
9. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007; 5(4):345-51. doi:10.1016/j.amjopharm.2007.12.002 PMID: 18179993.
10. Safran DG, Neuman P, Schoen C, Kitchman MS, Wilson IB, Cooper B, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood). 2005; Suppl Web Exclusives: W5-152-W5-66.
11. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365(21):2002-12. doi:10.1056/NEJMsa1103053 PMID: 22111719.
12. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-Analysis of prospective studies. JAMA. 1998; 279(15):1200-5. PMID: 9555760.
13. Sikdar KC, Dowden J, Alaghehbandan R, MacDonald D, Peter P, Gadag V. Adverse drug reactions in elderly hospitalized patients: A 12-year population-based retrospective cohort study. Ann Pharmacother. 2012; 46(7-8):960-71. doi:10.1345/aph.1Q529 PMID: 22739715.
14. Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014; 20(5):146-56. PMID: 25326929.
15. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014; 15(5):655-65. doi:10.2217/pgs.14.6PMID: 24798722.
16. Hocum BT, White JR Jr., Heck JW, Thirumaran RK, Moyer N, Newman R, et al. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm. 2016; 73(2):61-7. doi:10.2146/ajhp150273 PMID: 26721535.
17. Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016; 19(3):213-28. doi:10.3111/13696998.2015.1110160 PMID: 26478982.
18. Azhar Gohar WJ, Ashcraft K, Neradilek MB, Newman RL, Thirumaran RK, Moyer N and Sass R. Differences in Medicare Quality Measures among Nursing Homes after Pharmacogenetic Testing. Journal of Research and Development. 2016; 4(1).
19. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. US Food & Drug Asministration. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm.
20. Table of pharmacogenomic biomarkers in drug labeling FDA. 2015.
21. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2016.
22. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015; 98(2):127-34. doi:10.1002/cpt.147PMID: 25974703.
23. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015; 98(1):19-24. doi:10.1002/cpt.113 PMID: 25801146
24. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90(4):625-9. doi:10.1038/clpt.2011.185 PMID: 21900891.
25. Searcy, Arkansas Population: Census 2010 and 2000 interactive map, demographics, statistics, quick facts. Census Viewer. 2010; http://censusviewer.com/city/AR/Searcy.
26. FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal FunctionStudy Design, Data Analysis, and Impact on Dosing and Labeling. Silver Spring, MD: U.S. Food and Drug Administration, 2010; http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf.
27. Hajjar ER, Hanlon JT, Artz MB, Lindblad CI, Pieper CF, Sloane RJ, et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother. 2003; 1(2):82-9. PMID: 15555470.
28. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and co-medication dependent CYP2D6 metabolic activity: Effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016; 72(2):175-84. doi:10.1007/s00228-015-1965-1 PMID: 26514968.
29. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2016.
30. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296(15):1858- 66. doi:10.1001/jama.296.15.1858 PMID: 17047216.
31. Kahan BC, Morris TP. Adjusting for multiple prognostic factors in the analysis of randomised trials. BMC Med Res Methodol. 2013; 13:99. doi:10.1186/1471-2288-13-99 PMID: 23898993.
32. Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: An assessment of 12 outcomes from 8 studies. Trials. 2014; 15:139. doi:10.1186/1745-6215-15-139 PMID: 24755011.
33. Rizzo E. 6 Stats on the Cost of Readmission for CMS-Tracked Conditions. Becker's Hospital Review. Dec 12, 2013: http://www.beckershospitalreview.com/quality/6-stats-on-The-cost-of-readmission-forcms-Tracked-conditions.html.
34. K MLaC. Trends in Health Care Expenditures for the Elderly, Age 65 and Over: 2001, 2006, and 2011 Rockville (MD): Agency for Healthcare Research and Quality. Jan 3, 2014: http://meps.ahrq.gov/mepsweb/data-stats/Pub-ProdResults-Details.jsp?pt=Statistical%20Brief&opt=2&id=1129.
35. Alagoz O, Durham D, Kasirajan K. Cost-effectiveness of one-Time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenomics J. 2016; 16(2):129-36. doi:10.1038/tpj.2015.39 PMID: 25987241.
36. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Affairs (Millwood). 2008; 27(3):759-69.